Incretin Atlas › Trials › HDM1002-301
HDM1002-301
HDM1002 · obesity
Design
- Molecule(s)
- HDM1002
- Population
- obesity
- Phase
- 3
- Participants
- 857
- Duration
- 52 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 200 mg QD | obesity china | 52 | 857 | −10.7 % vs −1.5 % Δ −9.2 pp | −9.4 % vs −1.5 % Δ −7.9 pp | — | 1.5 vs 0.6 | — | — | — | — | — | press release |
| 400 mg QD | obesity china | 52 | 857 | −12.2 % vs −1.5 % Δ −10.7 pp | −11.3 % vs −1.5 % Δ −9.8 pp | — | 2.0 vs 0.6 | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (6)
- 200 mg QD · weight_eff · HKEX filing
第 52 周 -10.7% -12.2% -1.2%
- 200 mg QD · weight_tp · HKEX filing
第 52 周 -9.4% -11.3% -0.9%
- 200 mg QD · ae_dc · 四、安全性 paragraph
因 AE 导致的治疗终止率分别为 1.5% (HDM1002 片 200mg 组)、2.0%(HDM1002 片 400mg 组)和 0.6% (安慰剂组)
- 400 mg QD · weight_eff · HKEX filing
第 52 周 -10.7% -12.2% -1.2%
- 400 mg QD · weight_tp · HKEX filing
第 52 周 -9.4% -11.3% -0.9%
- 400 mg QD · ae_dc · 四、安全性 paragraph
因 AE 导致的治疗终止率分别为 1.5% (HDM1002 片 200mg 组)、2.0%(HDM1002 片 400mg 组)和 0.6% (安慰剂组)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: HDM1002-301. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/hdm1002-301/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.